文献速递消化道肿瘤与早癌

靶向CHK1治疗清除DNA复制应激、p53缺陷的超二倍体结直肠癌干细胞

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
PubMed 文献 · Gut · 2017-04-07

研究从27例患者分离的结直肠癌干细胞富集原代细胞中筛选FDA批准或研究性药物,发现LY2606368通过抑制CHK1在体外和体内清除约36%患者的肿瘤细胞。敏感细胞显示DNA复制应激反应标志物磷酸化RPA32和ATM,与TP53突变及超二倍体相关,且不依赖RAS突变状态。

要点

  • LY2606368通过抑制CHK1迫使复制应激的结直肠癌干细胞进入过早致死性有丝分裂。
  • 敏感结直肠癌干细胞表现为RPA32和ATM磷酸化、TP53突变及超二倍体。
  • LY2606368对RAS突变型结直肠癌干细胞同样有效,不依赖RAS突变状态。

核心结论

  • LY2606368选择性清除复制应激、p53缺陷和超二倍体的结直肠癌干细胞,不依赖RAS突变状态。
  • 结果为在结直肠癌患者中开展基于生物标志物的LY2606368临床试验提供了有力依据。

研究设计与样本

  • 研究对来自27例患者的结直肠癌干细胞富集原代细胞进行FDA批准或研究性药物库筛选。
  • 通过整合基因组、反相蛋白微阵列和细胞遗传学分析识别并验证候选预测生物标志物。
  • 采用DNA复制干扰或多倍体化药物增加DNA复制应激。

主要发现

  • 药物库筛选鉴定出LY2606368为强效抗结直肠癌干细胞药物,在体外和体内对相当数量患者(约36%)的肿瘤细胞有效。
  • LY2606368抑制CHK1影响多数结直肠癌干细胞的DNA复制,包括RAS突变者,迫使其进入过早致死性有丝分裂。
  • 对LY2606368敏感的结直肠癌干细胞显示持续DNA复制应激反应迹象,包括RPA32和ATM磷酸化,并与TP53突变和超二倍体相关。
  • 实验性增加DNA复制应激可使耐药的结直肠癌干细胞对LY2606368敏感。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies. DESIGN: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents. RESULTS: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (∼36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368. CONCLUSIONS: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Manic G, Signore M, Sistigu A, et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut. 2017. PMID: 28389531. doi:10.1136/gutjnl-2016-312623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。